Oxford BioMedica gets US approval for gene therapy trial

Oxford BioMedica Plc has received approval from the US Food and Drug Administration to start a first human study of its gene therapy for Usher syndrome, a genetic disorder that affects hearing and vision. The study will take place in Oregon.